ArticleWorld journal of microbiology & biotechnology2025
Pyrrolnitrin is integral for antimicrobial activity and phenazine biosynthesis of Pseudomonas chlororaphis strains.
Article in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Pseudomonas species are recognized for producing a diverse array of microbial metabolites with significant potential across various fields. Pyrrolnitrin (PRN), a halogenated metabolite based on phenylpyrrole, exhibits potent antibiotic properties. This research aimed to examine the influence of pyrrolnitrin on the antagonistic properties of Pseudomonas chlororaphis strains PB-St2, FS2, and RP4. Mutants of P. chlororaphis were generated by inhibiting prnA using two distinct suicide vectors, pEX18Tc and pKC1132. Analysis via high performance liquid chromatography (HPLC) revealed that pyrrolnitrin production was completely eliminated in the pKC1132 mutant and decreased by 82.5% in the pEX18Tc mutant. Both mutants also exhibited reduced phenazine production, with pKC1132 mutants showing a 61.1% reduction in phenazine-1-carboxylic acid (PCA) and pEX18Tc-induced mutants displaying a 39.9% decrease in PCA. To further elucidate the dependence of pyrrolnitrin production on other regulatory elements, the complete prnABCD operon with its native promoter was cloned and expressed in Escherichia coli (BL21). The antimicrobial potential of purified pyrrolnitrin was evaluated against fungal plant pathogens, human bacterial pathogens, and cancer cell lines (HepG-2 and SF767). The most pronounced inhibitory effect on Alternaria alternata was observed with 100 µg of pyrrolnitrin, resulting in an 82% reduction in spore formation followed by its effect on Aspergillus niger, causing a 75% decrease in spore production. Pyrrolnitrin's antibacterial activity produced inhibition zones of 1.8 cm against Salmonella enterica, 3.4 cm against Bacillus cereus, and 1.4 cm against Staphylococcus sp. at a concentration of 75 µg. The antiproliferative effects of pyrrolnitrin on cancer cell lines demonstrated 50% inhibition of both HepG-2 and SF767 cell lines at concentrations of 15 µg and 25 µg, respectively. Pyrrolnitrin exhibited significant antifungal and antibacterial activities, as well as cytotoxic effects on cancer cell lines, indicating its potential as both a biocontrol agent and therapeutic compound.
Indexed as
Identifiers
40415130What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.